Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies

Acute myeloid leukemia (AML) is a heterogeneous blood-related neoplasm that predominantly afflicts older adults with a poor prognosis due to their physical condition and the presence of medical accompanying comorbidities, adverse biological disease features, and suitability for induction intensive c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, Marco Giovannini, Carla Mazzone, Nelida Ines Noguera, Paolo de Fabritiis
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Current Oncology
Subjects:	genomic profiling targeted therapies hypomethylating agents venetoclax-based combinations intensive chemotherapy transplantation clinical trials
Online Access:	https://www.mdpi.com/1718-7729/31/11/490
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of hypomethylating agents in the treatment of AML/MDS patients relapsed post allogenetic hematopoietic stem cell transplantation
by: Yaxin Wang, et al.
Published: (2024-12-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID
by: Antonio Cristiano, et al.
Published: (2022-04-01)

Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review
by: Ziwei Zhou, et al.
Published: (2024-12-01)

Pseudo-differentiation syndrome
by: Fathi Jehani, et al.
Published: (2011-01-01)

Pseudo-differentiation syndrome
by: Dina Khalaf, et al.
Published: (2011-12-01)

Effect of hypomethylating agents on prognosis in acute myeloid leukemia patients treated with HAG priming: a systematic review and meta-analysis
by: Jun Li, et al.
Published: (2024-12-01)

Hypoxia impairs decitabine-induced expression of HLA-DR in acute myeloid leukaemia cell lines
by: Sam Humphries, et al.
Published: (2025-01-01)

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
by: Lauro Fabián Amador-Medina, et al.
Published: (2024-12-01)

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial
by: Jorge E. Cortes, et al.
Published: (2025-01-01)

Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country
by: Quang Hao Nguyen, et al.
Published: (2025-01-01)

Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
by: Xushu Zhong, et al.
Published: (2024-12-01)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia
by: Wing Fai Li, et al.
Published: (2024-11-01)

Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
by: Wen-Jing Yu, et al.
Published: (2024-12-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
by: Musa Fares Alzahrani
Published: (2024-12-01)

Targeting mitochondrial RNAs enhances the efficacy of the DNA-demethylating agents
by: Stephanie Tan, et al.
Published: (2024-12-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

Left Kidney Undifferentiated Spindle Cell Sarcoma with Myeloid Cell Leukemia-1 Amplification: Therapeutic Response to Bortezomib, Venetoclax, and Dexamethasone Therapy
by: Cheng-Yu Tang, et al.
Published: (2023-10-01)

Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases
by: Enrico Derenzini, et al.
Published: (2024-12-01)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia
by: Jingying Cui, et al.
Published: (2024-12-01)

Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis
by: Hongbo He, et al.
Published: (2024-12-01)

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
by: Fei Xin, et al.
Published: (2024-12-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

Combination Treatment of Resistant Acute Promyelocytic Leukemia Cells with Arsenic Trioxide and Anti-Apoptotic Gene Inhibitors
by: Manuela Giansanti, et al.
Published: (2024-11-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
by: Juan Li, et al.
Published: (2025-12-01)

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)

An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers
by: Vinod K. Ramani, et al.
Published: (2025-01-01)

First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid
by: Li Zhu, et al.
Published: (2024-12-01)

Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with RUNX1 mutation
by: Emiko Kashima, et al.
Published: (2024-12-01)

Comparison of autologous hematopoietic cell transplantation, matched sibling donor hematopoietic cell transplantation, and chemotherapy in patients with favorable- and intermediate-risk acute myeloid leukemia
by: Mingyang Wang, et al.
Published: (2025-01-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
by: Sofija Kozarac, et al.
Published: (2025-01-01)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

High expression of EBP is an adverse prognostic factor for de novo acute myeloid leukemia
by: Jiaying Lian, et al.
Published: (2024-12-01)

Impact of Chemotherapy on the hematological parameters of Acute Myeloid Leukemia Iraqi patients
by: Noorhan S. Resn, et al.
Published: (2024-12-01)

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
by: Stefano Molica, et al.
Published: (2021-06-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

6-month survival of patients with acute myeloid leukemia who received modified chemotherapy at Wahidin Sudirohusodo Hospital
by: Edwinda D. Ratu, et al.
Published: (2024-09-01)